TerrAscendTSNDF +2.79%32 EBITDA Margin % is 26.99% as of Mar. 2026. GuruFocus rates TSNDF with a GF Score™ of 32/100 and a GF Value™ of $0.99 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 955 Drug Manufacturers companies, TerrAscend ranks better than 74.97% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. TerrAscend's EBITDA for the
three
months ended in Mar. 2026 was $17.7 Mil. TerrAscend's Revenue for the
three
months ended in Mar. 2026 was $65.5 Mil. Therefore, TerrAscend's EBITDA margin for the quarter that ended in Mar. 2026 was 26.99%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
TerrAscend EBITDA Margin % Related Terms
TerrAscend EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for TerrAscend's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, TerrAscend's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TerrAscend EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, TerrAscend's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where TerrAscend's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TerrAscend (TSNDF) has a EBITDA Margin % of 26.99% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on TerrAscend and its competitors. According to the industry distribution chart, TerrAscend ranks #239 out of 955 companies in the Drug Manufacturers industry, placing it in the top 25%.
Is TerrAscend's EBITDA Margin % too high?
TerrAscend's current EBITDA Margin % is 26.99%. The Drug Manufacturers industry median EBITDA Margin % is 12.39. TerrAscend's value of 26.99% is 117.8% above this industry median. Based on the distribution chart, TerrAscend ranks #239 out of 955 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, TerrAscend has a GF Score™ of 32/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does TerrAscend's EBITDA Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, TerrAscend ranks #239 out of 955 companies for EBITDA Margin %. This places TerrAscend in the top 25% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 12.39. TerrAscend's value of 26.99% is 117.8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.39, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. TerrAscend's current EBITDA Margin % of 26.99% is 117.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on TerrAscend and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. TerrAscend's current EBITDA Margin % is 26.99%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TerrAscend stock overvalued right now?
Based on GuruFocus' analysis, TerrAscend (TSNDF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.99, compared to a current price of $0.65 — trading 34.8% below its estimated fair value. The current EBITDA Margin % is 26.99% and 117.8% above the Drug Manufacturers industry median of 12.39. TerrAscend's overall GF Score™ is 32/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For TerrAscend (TSNDF), the current EBITDA Margin % is 26.99% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is TerrAscend (TSNDF) Overvalued in 2026?
Based on GuruFocus' analysis, TerrAscend stock appears to be undervalued.
The current stock price of $0.65 is trading 34.8% below its estimated GF Value™ of $0.99.
GuruFocus considers TerrAscend to be Possible Value Trap.
Key valuation signals for TSNDF:
EBITDA Margin %: 26.99%
GF Value™: $0.99 vs. price of $0.65 (34.8% below fair value)
Industry Position: 117.8% above the Drug Manufacturers median (#239 of 955)
No single metric tells the full story. See the TSNDF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
TerrAscend Corp is a company focused on creating and delivering cannabis products and services that meet the evolving needs of its patients. It also provides education and support programs to physicians and patients through healthcare professionals. In addition, the firm operates in California, Maryland, New Jersey, and Pennsylvania, with retail operations in Ohio and Canada. It operates The Apothecarium and other dispensary retail locations as well as scaled cultivation, processing, and manufacturing facilities in its core markets. The firm has one operating segment, being the cultivation, production, and sale of cannabis products, with subsidiaries located in Canada and the United States. The company generates key revenue from the United States.
32GF Score
Get the complete analysis for TSNDF
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSNDF has been successfully added to your 
